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Abstract:  
Introduction and objectives: There is a paucity of antipsychotic prescribing and utilization data in 
Pakistan. This needs addressing especially with issues of availability, affordability, gender differences, 
and domestic violence, to develop pertinent strategies. The objective of this study was to address 
these issues by describing current antipsychotic utilization patterns in Pakistan among adult patients 
attending tertiary care hospitals and private practitioners. Methods: A three staged approach was 
used including 1/ assessment of total antipsychotic utilization, expenditure and costs per unit between 
2010 and 2015, 2/ an in-depth retrospective study of prescribing patterns including co-morbidities 
among representative hospital patients in Pakistan, and 3/ assessment of the quality of prescribing 
against WHO targets. Results: Total use of antipsychotics increased 4.3-fold and the cost/unit 
increased by 13.2% during the study period. Risperidone and olanzapine were the most prescribed 
antipsychotics with more limited use of other typical and atypical antipsychotics. The number of 
medicines per encounter was 4.56. Prescription using generic instead of brand names was 21.4%. 
Seven percent was prescribed more than one antipsychotic concurrently. Conclusion: There has 
been an appreciable increase in anti-psychotic utilization in recent years in Pakistan especially 
atypical antipsychotics, with little polypharmacy. Ongoing utilization of typical antipsychotics may be 
due to comorbidities such as diabetes and cardiovascular disease. Issues of international non-
proprietary name prescribing need investigating along with the high number of medicines per 
encounter and gender inequality. 
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1. Introduction  
 
Medicines including vaccines are a fundamental part of health care as they do not only help to reduce 
morbidity and mortality, but also help to prevent epidemics and illnesses. Consequently, access to 
appropriate medicines should be an essential right of every person (1, 2). Mental disorders account 
for 10 to 13% of the global burden of disease, although others have documented higher rates (3-9). 
However, currently only a minority of people affected by mental health receive basic treatment (6, 9-
11). Whereas there is evidence from higher income countries that not all people with mental disorders 
receive adequate treatment, this is worse in low and middle income countries (LMICs) where mental 
health services are traditionally lacking, and large segments of the population do not have ready 
access to health care or receive inadequate care (9, 10, 12, 13). Where services exist in LMICs, these 
tend to be based in hospitals and oriented predominantly towards urban conditions, although 
community care is now increasing (6).   
 
The introduction of antipsychotics was a major breakthrough in the field of psychiatry, leading to their 
inclusion in a number of guidelines as well as Essential Medicine Lists (EML) across countries to 
enhance rational prescribing (9, 14-19). However, despite the plethora of guidelines, in clinical 
practice prescribing can differ appreciably from the suggestions (20-23).  
 
Extrapyramidal side-effects are a concern with all antipsychotics, with the difference between first and 
second generation antipsychotics in terms of their development now less clear cut, although more 
likely to occur with first generation antipsychotics (24-26). Consequently, the treatment of 
schizophrenia and bipolar disorders should be tailored to individual patients, which is typically the 
case in developed countries (27, 28). This has resulted in changes in prescribing patterns as different 
antipsychotic medicines become available (29), with the World Health Organisation (WHO) EML 
recommending chlorpromazine, fluphenazine, haloperidol, with potentially risperidone depending on 
costs (9). Anticholinergic medicines have also been used to alleviate neuroleptic-induced 
extrapyramidal side-effects ((30). However, there are concerns with their use including cognitive 
effects, altered absorption of other oral medications and abuse potential (31). Short-term use may 
help prevent this in most patients (30).   
 
One important side effect of many antipsychotics is weight gain (23, 32-35), although there appears to 
be less of an issue with amisulpride and aripiprazole (36) as well as potentially with risperidone 
among patients in Pakistan (35). The mechanisms for this are not well understood; however, factors 
such as sedation, decreased satiety, lack of movement as well as endocrine changes resulting in 
increased appetite and food intake, may well play a role (34, 37). In addition, schizophrenia itself is 
associated with higher rates of obesity and diabetes (35, 38). This is a concern given the increasing 
prevalence of diabetes worldwide, necessitating regular review of antipsychotic treatment (39). This is 
especially important in developing countries such as Pakistan with growing rates of obesity and 
diabetes (40, 41).  
 
There are also concerns with antipsychotic polypharmacy in a number of countries (9, 22, 42-44), 
which has been linked with increased adverse events including the metabolic syndrome (45-47), 
increasing costs (42, 48) and lowering medication compliance (49). Consequently, schizophrenia 
treatment guidelines typically emphasize antipsychotic monotherapy (16, 22, 50). Despite this, 
antipsychotic polypharmacy can be common with published studies showing a broad range of 
polypharmacy rates from 4.1% to 48.0% (9, 21, 22, 51-55) depending on the study method and 
patient characteristics. Sim et al reported rates of antipsychotic polypharmacy at 45.7% in East Asia 
with wide intercountry variations, with the rates likely to be influenced by the clinical settings as well 
as cultural and personal practice factors (54). The high rate of polypharmacy may indicate that 
available pharmacological treatments and treatment guidelines are still far from meeting all needs 
(55). Alternatively, issues such as compliance may be a problem with additional treatments added 
before exploring these factors further and potentially switching formulations or modes of 
administration (56, 57).  
 
The management of patients with mental health conditions continues to be a concern in Pakistan, 
which is not help by the continuing violence in some regions (58). Overall, mental illness affects 
between some 10 – 16% of the population or more (59, 60); with a large majority of those affected 
being women. It is estimated there is only one psychiatrist for every 10000 people and one 
psychiatrist for 4 million children in Pakistan suffering from psychiatric conditions (60), although others 
have estimated psychiatrist-to-person ratios up to 1 to half a million people (61). Due to the scarcity of 
psychiatrists, the management of mentally ill patients may be inadequate. However, this lack of health 
care professionals is also common in other LMIC countries (6). 
 
Mental health has continued to remain a subject of considerable debate in Pakistan, with the 
incidence and prevalence of mental disorders increasing against a background of growing insecurity, 
terrorism, political uncertainty, unemployment and disruption of the social fabric (58, 62). This is not 
helped by the fact that social acceptance is crucial to an individual’s livelihood and vitality in Pakistan, 
which includes getting married, working, socializing, and daily functioning. Unfortunately, people in 
Pakistan are typically unwilling to socialize with someone who suffers from mental disorders, 
exacerbated by oversimplified ideas about individuals based on a particular category, ongoing 
prejudices, as well as discrimination. This leads to active discrimination towards individuals with 
mental disorders in Pakistan. Anxiety, depression, and schizophrenia can frequently be written off, 
with sufferers told to bolster their faith to reduce the disease. This is a concern as there are medicines 
and other strategies available to help address mental health disorders. However, inaccessibility to 
mental healthcare, as well as beliefs that psychiatric illness may be due to evil spirits and the neglect 
of ritual obligations, can result in patients approaching local religious healers, faith healers, hakims, or 
practitioners of homeopathic medicine, and potentially ultimately finding only limited relief (63, 64).   
Pakistani women face an even greater risk as they can be targets of domestic violence and there are 
continuing concerns with gender-inequality including management of diseases such as mental health 
disorders. In addition, 39% of the citizens currently live below the poverty line in Pakistan adding to 
stresses of daily life, although there has been an improvement in recent years (65). Encouragingly, 
more people are now presenting to mental health professionals as a result of the growing awareness 
of their abilities. However, there is a continued concern that a large number of Pakistani psychiatrists 
emigrate to other countries including Australia, Canada, New Zealand, Middle East, UK and USA 
(62).   
 
To date, there have been relatively few studies reporting on mental health conditions in Pakistan. 
Those that have been published include studies on common psychiatric disorders in outpatient care, 
general and major depressive disorders, factors associated with psychotic relapses and non-
adherence of anti-psychotic medicines, gender differences in response to antipsychotics, cognitive 
disorders, and prescribing preferences of mental health professionals (7, 13, 64, 66-71). However, we 
are not aware of any study that has comprehensively assessed utilization and expenditure patterns of 
antipsychotic medicines across Pakistan as a first step to improving treatment options if concerns.  
Consequently, the objective of this study was to describe current antipsychotic utilization patterns in 
Pakistan and, more specifically, in adult patients attending tertiary care hospitals and private 
practitioners. This includes a comprehensive documentation of drug utilization patterns in recent 
years in accordance with WHO suggestions for LMICs (9). Subsequently, the findings will be used to 
suggest future research and initiatives in Pakistan to help improve the management of these patients, 
especially in view of the growing toll of neglecting mental health disorders among patients in LMICs, 
building on recent WHO recommendations.  
  
2. Materials and Methods  
 
The research was divided into three parts. Part one involved documentation of the utilization and 
expenditure patterns for antipsychotic medicines across Pakistan. This was undertaken to provide a 
benchmark for assessing whether the more detailed analysis of prescribing patterns in two Pakistani 
hospitals were representative. The second part involved researching the database of hospitals in 
Rawalpindi and Islamabad to gain a greater insight into antipsychotic prescribing patterns. This 
included evaluating the extent of co-morbidities, international non-proprietary name (INN) prescribing, 
and polypharmacy. The utilization patterns were appraised in terms of their respective prescribing 
patterns of both typical and atypical antipsychotics to see if there were similarities between the two 
databases. In this way, the representativeness of the hospital data could be assessed against 
antipsychotic utilization patterns across Pakistan to enhance the robustness of any suggestions made 
regarding potential future initiatives and research. The third part involved assessment of current 
utilization patterns against recognized WHO criteria to again provide suggested initiatives in the future 
to improve prescribing if concerns (72).     
 
2.1 Part One - Utilization and expenditure of antipsychotic medicines across Pakistan  
Utilization and expenditure data for the antipsychotics (N05A group apart from Lithium – N05AN (73)) 
from 2010 to 2015 were extracted from Intercontinental Marketing Services (IMS – now 
QuintilesIMSTM) data to provide insight into current utilization and expenditure patterns. IMS collects 
data of drug statistic sales from a representative sample of pharmacies in Pakistan to provide 
representational data for Pakistan, with IMS data internationally recognized for comparing drug 
utilization statistics across countries (29, 74). IMS data was sourced via the Drugs Regulatory 
Authority in Pakistan (DRAP) for academic purposes. The utilization units are IMS units, which are 
typically based on packs dispensed including their strength and number of tablets.   
The data was further broken down into utilization and expenditure of the most utilized typical 
antipsychotics, e.g. chlorpromazine (N05AA01), fluphenazine (N05AB02), and haloperidol (N05AD01) 
as well as atypical antipsychotics, e.g. aripiprazole (N05AX12), clozapine (N05AH02), olanzapine 
(N05AH03), and risperidone (N05AX08), in terms of percentage share by value and units for 
comparative purposes.   
 
Different brands of risperidone and olanzapine were also documented to see if appreciable 
competition would help to lower prices as seen in countries such as the Netherlands (75). This 
included different branded generics, which are common in Pakistan, with competition to potentially 
reduce prices seen as important given current high co-payment levels for medicines in Pakistan (76).   
The value of medicines has been documented in Pakistan Rupees [85 - 105 Pakistan Rupees = 1 
US$ - average from 2010 to 2015] (77). 
 
2.2 Part Two - Hospitals in Rawalpindi and Islamabad   
The database of adult (≥ 18 years) patients receiving any antipsychotic medicine in the outpatient 
departments of both public and private hospitals in Rawalpindi and Islamabad was retrieved from May 
2016 to October 2016. These two cities were chosen as they are representative of other cities in 
Pakistan (76).   
 
A standard data collection form was used to collect information on patient demographics including 
sex, age (as documented from the patient’s medical journal), psychiatric diagnosis (based on DSM IV 
codes), comorbidities, current medicines for mental health conditions and the length of treatment as 
well as any concomitant drugs from the medical journal of the patients, which are paper based.   
Overall, the records of 5460 patients were retrieved and searched by hand by SM and TUR. This 
included the prescribing of antiepileptics (N03A), anti-parkinson medicines (N04A), antipsychotics 
(N05A), anxiolytics (N05B), and hypnotics and sedatives (N05C). The top 20 medicines by INN name 
were subsequently tabulated. This included the most common medicines for patients with mental 
health including antipsychotics, which enabled the utilization of antipsychotics in these two cities to be 
compared with the total population in Pakistan to give future guidance given the lack of electronic 
databases in Pakistan. This is important when reviewing the extent of co-prescribing of antipsychotics 
as well as the co-prescribing of other medicines based on the extent of co-morbidities. Such 
information is not available from the IMS database interrogated.   
  
2.3 Part 3 – Assessing the quality of prescribing  
The WHO indicators were used to initially assess the quality of prescribing for patients with mental 
health in the two cities including the antipsychotics. The quality of prescribing was assessed against 
pre-set goals (72, 78-80), which included the average number of medicines per prescriptions (<2), the 
rate of INN prescribing (100%), and the percentage of medicines prescribed from the national EML list 
(NEML) (100%) (80).   
 
In addition, the quality of prescribing was further assessed by looking at the extent of any co-
prescribing of antipsychotic medicines.  
  
2.4 Statistical Analysis 
Descriptive statistics were used to describe the utilization patterns. Univariate linear regression was 
used to evaluate the changes in the utilization (total consumption, total expenditure, percentage share 
by unit and value) over time, with time (the years 2010 to 2015) as the independent variable. A p-
value of <0.05 was considered statistically significant. Data analysis was performed using SPSS 16.  
 
2.5 Ethical Approval  
Ethical approval was sought and obtained from the Medical Ethics Committee at Quaid e Azam 
University, Islamabad, Pakistan, before conducting the study.  
  
3. Results  
 
3.1 Utilization and cost data for Pakistan (IMS Data)  
From 2010 to 2015 there was a progressive rise in the use and expenditure of antipsychotics in 
Pakistan (Table 1), with the population also growing.   
 
Table 1 - Details of antipsychotic consumption and expenditure in Pakistan (2010-2015) based on 
IMS data 
 
Year Total Number of 
Units* 
Total Sale in Pak 
Rupees (Rs) ** 
Population 
(in Millions)**** 
Cost per unit 
Rupees Rs (US 
$)*** 
2010 3,216,920 552,081,540 173.5 171.61 (2.06) 
2011 6,697,542 1,175,229,819 175.31 175.47 (1.99) 
2012 7,469,569 1,358,045,338 178.91 181.81 (1.94) 
2013 12,121,154 2,168,676,902 182.52 178.92 (1.75) 
2014 12,549,712 2,429,619,514 189.87 193.60 (1.88) 
2015 13,845,897 2,689,138,970 196.56 (1.89) 
 Extent of 
change 
(absolute) 
4.30 4.87 1.13 1.13 
NB: * P=0.001; ** p=0.003; *** p=0.006; **** Population figures taken from (81). Units = IMS Units. Source: IMS 
2016.  
 
Antipsychotic utilization in Pakistan has been dominated by risperidone and olanzapine in recent 
years (Table 2), with a significant decrease in the percentage share by value but not utilization of 
risperidone. There was a significant increase in the percentage share by value and units of 
fluphenazine, with a corresponding decrease in the value and utilization of haloperidol. The share by 
value of aripiprazole (% of total units) also decreased but from a low base, although utilization has 
marginally increased in recent years but also from a low base. There was a mixed pattern with the 
other antipsychotics in terms of their utilization and expenditure over the years.  
 
  
Table 2: Percentage share and growth by value and units of the highest  utilized antipsychotic 
medicines in Pakistan  (negative or positive growth) from 2010 to 2015  
 
Antipsychotic (N05A) 
Year P value 
2010 2011 2012 2013 2014 2015  
Risperidone (N05AX08)  
% share by value 57.1 55.0 55.9 44.4 41.8 44.3 0.018 
% share by units 41.9 40.2 40.9 34.8 35.2 39.6 0.23 
% Growth against previous year by value - 8.1 17.4 17.7 4.4 15.8  
% Growth against previous year by units - 9.7 13.2 23.8 4.2 22.8  
Number of formulations available (recorded in IMS data): 20  
Olanzapine (N05AH03)  
% share by value 20.5 22.2 21.4 20.5 19.7 19.2 0.101 
% share by units 27.9 30.1 29.5 29.9 28.6 27.2 0.49 
% Growth against previous year by value - 21.9 11.3 41.8 6.6 6.3  
% Growth against previous year by units - 23.3 9.1 47.5 -1.7 3.8  
Number of formulations available (recorded in IMS data): 20  
Clozapine (N05AH02)  
% share by value 7.7 7.2 6.9 4.9 8.4 9.5 0.47 
% share by units 0.5 0.5 0.5 0.3 0.7 0.8 0.23 
% Growth against previous year by value - 5.5 9.8 4.8 91.8 23.1  
% Growth against previous year by units - 5.9 10.9 3.1 120.2 15.8  
Number of formulations available (recorded in IMS data): 4  
Fluphenazine (N05AB02)  
% share by value 5.2 6.0 7.4 16.9 17.3 14.6 0.029 
% share by units 9.6 10.2 12.6 19.2 20.0 17.1 0.028 
% Growth against previous year by value - 26.9 42.1 241.6 13.5 -7.7  
% Growth against previous year by units - 21.4 38.2 119.8 7.2 -6.4  
Number of formulations available (recorded in IMS data): 10  
Haloperidol (N05AD01)  
% share by value 4.3 4.2 3.3 2.6 2.1 2.0 0.001 
% share by units 15.8 14.4 12.7 9.6 8.3 7.6 0.001 
% Growth against previous year by value  10.8 -8.6 15.2 -11.2 3.2  
% Growth against previous year by units  4.2 -1.8 9.8 -11.3 0.6  
Number of formulations available (recorded in IMS data): 4  
Aripiprazole (N05AX12)  
% share by value 2.1 2.0 1.7 1.4 1.8 1.9 0.007 
% share by units 1.6 1.5 1.3 1.2 1.8 1.8 0.91 
% Growth against previous year by value  5.9 -3.4 26.3 41.5 11.6  
% Growth against previous year by units  7.9 -2.5 32.1 57.1 7.5  
Number of formulations available (recorded in IMS data): 4  
Trifluoperazine (N05AB06)  
% share by value 1.9 2.2 1.8 1.3 1.0 0.8 0.002 
% share by units 1.8 2.2 1.6 1.3 1.5 2.2 0.006 
% Growth against previous year by value  30.6 -4.6 4.8 -17.9 -6.4  
% Growth against previous year by units  35.6 -20.6 17.1 23.2 60.0  
Number of formulations available (recorded in IMS data): 2  
Flupentixol (N05AF01)  
% share by value 1.1 1.1 1.5 2.7 3.4 3.6 0.06 
% share by units 0.6 0.7 0.8 1.9 2.2 2.2 0.17 
% Growth against previous year by value - 9.4 66.4 161.2 40.3 15.4  
% Growth against previous year by units - 19.1 29.6 252.0 18.2 10.6  
Number of formulations available (recorded in IMS data): 7  
Chlorpromazine (N05AA01)  
% share by value 0.1 0.1 0.0 0.0 0.0 0.0 0.06 
% share by units 0.2 0.1 0.1 0.0 0.0 0.1 0.17 
% Growth against previous year by value - -27.1 -12.5 -43.7 -25.2 119.2  
% Growth against previous year by units - -32.2 -35.3 -44.5 12.6 144.5  
Number of formulations available (recorded in IMS data): 6  
Ziprasidone (N05AE04)  
% share by value 0.0 0.0 0.0 3.5 2.8 2.5 0.058 
% share by units 0.0 0.0 0.0 1.2 0.9 0.7 0.093 
% Growth against previous year by value - - - 100.0 -13.1 -2.9  
% Growth against previous year by units - - - 100.0 -21.6 -18.4  
Number of formulations available (recorded in IMS data): 5   
Zuclopenthixol (N05AF05)  
% share by value 0.0 0.0 0.0 1.7 1.7 1.7 0.02 
% share by units 0.0 0.0 0.0 0.8 0.8 0.8 0.02 
% Growth against previous year by value - - - 100.0 9.6 10.7  
% Growth against previous year by units - - - 100.0 6.5 9.5  
Number of formulations available (recorded in IMS data): 3  
NB. Units = IMS Units (usually a pack). Source: IMS 2016 
 
Tables 3a and 3b document the utilization of different branded generics and originators of risperidone 
and olanzapine during the study period.    
 
Table 3a – Utilisation of different brands of Risperidone in Pakistan (2010 to 2015) based on IMS data 
 
 Percentage Units of Risperidone from 2010-15 
 
Brand name 2010 2011 2012 2013 2014 2015 
    RISP 22 22 22 20 22 18 
    VEPRIDONE 13 11 14 16 18 13 
    RISPERDAL 8 8 8 7 6 5 
    ORIDONE 0 3 5 8 8 15 
    ESPIDONE 6 5 5 3 4 4 
    BUZON 8 8 7 6 5 4 
    NEORIS 6 8 8 11 8 6 
    RESPEROSE 0 0 0 0 0 8 
    RECEPT 6 6 4 3 3 4 
    PERSCH 4 5 4 4 5 4 
NB. Units = IMS Units. Source: IMS 2016 
 
Table 3b – Utilisation of different brands of olanzapine in Pakistan (2010 to 2015) based on IMS data 
 





2011 2012 2013 2014 2015 
    OLEPRA              35 33 37 29 28 22 
    OLANZIA             40 36 34 31 32 34 
    ZYPREXA             1 1 1 1 1 1 
    NIRVANOL           0 0 0 6 5 6 
    LEPINZA            0 0 0 5 6 6 
    OZAPINE             0 0 0 4 6 7 
    AMPREXA           5 9 8 7 6 6 
    ZANZIA              0 4 6 6 6 6 
    OZIP                0 0 0 0 0 2 
    OLAN                0 0 0 8 4 2 
    FURMIUM             0 0 0 7 1 2 
NB. Units = IMS Units. Source: IMS 2016 
 
3.2 Retrospective study (patient data) including analysis of quality indicators  
Among the 5460 patients treated with antipsychotics in Rawalpindi and Islamabad there were 1462 
(26.7%) women and 3978 (71.3%) men. Table 4 shows the distribution of the various age groups in 
the retrospective analysis. The maximum number of patients were in the age group 41-50 years 
(Table 4).  
 
  
Table 4 – Distribution of ages among the 5460 patients treated with antipsychotics 
Age (years) Number of patients (5460) Percentage (%) 
18 – 30 543 9.98 
31 – 40 1478 27.17 
41 – 50 1924 35.36 
52 – 60 1357 24.94 
> 60 642 11.80 
 
The number of patients diagnosed with schizophrenia were 2144 (39.4%), followed by bipolar 
disorders1390 (25.5%), depressive disorders 724 (2.07%) and anxiety disorders 113 (2.07%), 
insomnia 83 (1.52%) and other diagnoses 988 (18.16%).  
 
The total number of medicines prescribed were 24806, representing 142 different molecules.  The 
average number of medicines per prescription was 4.56 and the percentage of medicines prescribed 
by their generic name (INN) as opposed to a branded generic was 21.4% (Table 5). Less than 40% of 
medicines were prescribed from the NEDL.  
 
Table 5 – Assessment of prescribing practices among the 5460 patients treated with antipsychotics 
against WHO indicators (WHO targets adapted from references 70,78) 
 
Parameters Number/percentage WHO Target 
Total number of drugs prescribed among the 
5460 patients 
24806  
Average number of medicines/prescriptions 
(encounter) 
4.56 Less than 2, 
acceptable 
between 2 and 2.5 
Percentage of the drugs prescribed by 
generic name (INN) 
21.4%  100%, 
acceptable 80% 
Percentage of the drugs prescribed from the 
National Essential Drugs List  
Less than 40% 100% 
NB: INN = International non-proprietary name 
 
The most common psychotropic medicines prescribed were risperidone (31%), olanzapine (18.4%), 
procyclidine (8.4%), alprazolam (8.4%), and haloperidol (7.7%) (Table 6).   
 
Table 6 – Most common mental health medicines prescribed among the 5460 patients treated with 
antipsychotics 
 
Medicines Prescribed % of total mental health medicines 

















Lithium Carbonate 0.7 
Flupentixol 0.7 




NB: Unit = Prescription 
 
Antipsychotics were the most prescribed medicines among the mental health medicines (55.6% of 
total prescriptions), followed by antidepressants 29.6%, anxiolytics 1.9%, medicines for mania and 
mood stabilizers 4% (Table 7). Other medicines prescribed for these patients reflects the fact that 
many had other co-morbidities including hypertension, diabetes and cardiac problems (Table 8 and  
Appendix Table 1A).   
 
Table 7 – The breakdown of medicine classes prescribed (all medicines) among the 5460 patients 
treated with antipsychotics 
 
Category of Drugs No. of Patients Percentage (%) 
Anti-psychotics 3024 55.6 
% of patients prescribed one 
antipsychotic concurrently 
2813 93 
% of patients prescribed 2 
antipsychotics concurrently 
154 5.1 
% of patients prescribed more 
than 2 antipsychotics 
concurrently 
58 1.9 
Anti-depressants 1610 29.6 
% of patients prescribed one 
anti-depressant concurrently 
1345        83.02 
% of patients prescribed 2 anti-
depressants concurrently 
177 10.99 
% of patients prescribed more 
than 2 anti-depressants 
concurrently 
88 5.46 
Anti-manic/Mood stabilizers 220 4 
Anxiolytics 55 1.0 
Others 531 9.8 
NB: Unit = Prescription 
 
  




            Comorbidities  No. of 
patients 
Percentage (%) 
Schizophrenia 2142 39.4 
 Diabetes 334 15.6 
 HTN  313 14.6 
 Diabetes+ HTN 147 6.9 
 CVD  190 8.8 
 Diabetes+ HTN+ CV 42 2.0 
 Hyperlipidemia 37 1.7 
Bipolar Depression       1390  
 Diabetes 119 8.6 
 HTN 122 8.8 
 Diabetes+ HTN 103 7.4 
 CVD 87 6.3 
 Diabetes+ HTN+CVD 05 0.4 
 Migraine  27 2.0 
 Obesity  56 4.0 
 Eating Disorders 44 3.2 
Depression         724  
 Diabetes 51 7.0 
 HTN 11 1.5 
 Diabetes+ HTN 13 1.8 
 CVD 46 6.3 
 Diabetes+ HTN+ CVD 04 6.6 
 Hypothyroidism 32 4.4 
 Antisocial Personality Disorders 08 1.1 
 Obesity 21 2.9 
 Migraine 14 1.9 
Anxiety         113  
 Diabetes 07 6.2 
 HTN 11 9.8 
 Diabetes+ HTN 03 2.6 
 CVD 14 12.4 
 Diabetes+ HTN+ CVDs 02 1.8 
 Inflammatory bowel  syndrome 02 1.8 
 Hyperlipidemia 04 3.5 
Insomnia          83  
 Diabetes 06 7.2 
 HTN 10 12.0 
 Diabetes+ HTN 04 4.8 
 CVD 08 9.6 
 Diabetes+ HTN+CVD 08 9.6 
 Dementia 04 4.8 
 Gastric Problems 12 14.4 
 Migraine 04 4.8 
Others         988  
 Obesity 07 0.7 
 Smoking 32 3.2 
 Eating Disorders 15 1.5 
 Panic disorders 17 1.7 
 Simple phobia 31 3.1 
NB: Unit = Prescription; HTN = Hypertension, CVD = coronary vascular disease 
 
  
4. Discussion   
 
There has been a significant increase in the utilization of antipsychotics in Pakistan in recent years 
(Table 1), suggesting that more patients are being treated given the limited extent of antipsychotic 
polypharmacy (Table 7) and the comparably modest population growth (13.3%) during the study 
period (Table 1). The modest increase of cost/item (13.2%) during the period may also have 
promoted the wider use of antipsychotics (Table 1). The similarities with the high utilization of 
olanzapine and risperidone among the atypical antipsychotics and high utilization of haloperidol 
among the typicals in both data sets (Tables 2 and 6) gives credence to the suggestion that the 5460 
patients in the retrospective analysis are representative of Pakistan as a whole. 
  
The high ratio of atypical to typical antipsychotic utilization found in our study is similar to the ratios 
reported among Western countries, and higher than in other developing countries (82-88), which is 
encouraging. This may be helped by the competition among branded generic manufacturers to secure 
sales through reduced prices with high co-payments levels currently seen in Pakistan (76), with 
typically limited originator prescribing (Tables 3a and 3b). Potential reasons for any differences seen 
in the relative use of the different antipsychotics between countries may be due to the economic 
status of countries as well as the extent of any patient co-payments (82, 89).  This is illustrated by 
relatively low use of atypical antipsychotics in countries with low income levels (83, 90); although this 
appears not to be the case in Pakistan (Tables 1 and 6), helped perhaps by the low costs per pack 
dispensed (Table 1). Hopefully, as more atypical antipsychotics become available as low cost 
generics, with generics in some countries priced as low as 2% of pre-patent loss prices, such issues 
will disappear (27, 57, 75) and treatment can be tailored to the individual and their needs in line with 
recommendations (24). This is also in line with the recent WHO guidance on improving access to care 
and treatment for patients with mental health conditions in LMICs (9). Lower cost for generics should 
also help with compliance (91), with no differences in effectiveness seen in practice between good 
quality generic antipsychotics and originators (92-97). However, the quality of generics can be an 
issue in Pakistan (9, 98), leading to high use of branded generics (Tables 3a, 3b and 5) unless 
concerns with the quality of generics are adequately addressed.   
 
The continuing use of typical antipsychotics in Pakistan, especially for new cases, could also be due 
to the contraindications for atypical antipsychotics in patients with diabetes, or a high risk of diabetes, 
with the prevalence of diabetes up to 12% of adult males and growing in Pakistan (99), and glucose 
intolerance over 22% in some adult populations (100). Diabetes mellitus and hypertension were 
common comorbidities reported in our patients (Table 8 and Appendix A), potentially reducing the 
prescribing of atypical antipsychotics especially with currently low use of quetiapine and aripiprazole 
versus risperidone and olanzapine (Table 6), both of which have been associated with less weight 
gain (101, 102). Having said this, previous research among patients in Pakistan has suggested that 
the prescribing of risperidone does not increase the weight of Pakistani psychiatric patients (35). 
However, our data cannot further inform on this issue, because no clear time relation information was 
available in the patients’ notes and we did not question the patients. In addition, data about weight 
was largely missing from the patient records. Furthermore, those patients who had been taking typical 
antipsychotics for a long time, and still showing improvements, will continue to be prescribed these 
antipsychotics unless they lead to adverse effects or decrease effectiveness. This is in line with 
prescribing practices in developed countries, emphasizing that patients should continue on their 
medicines even when generic versions of other atypical antipsychotics become available unless there 
are good reasons to change (27, 28).  
 
Similar to other studies, more men were treated with antipsychotics in our study (44, 83) although 
others have shown different findings (84-86). We are not fully sure of the reasons for this. However, 
we will be exploring this further given general issues with mental illness among women in Pakistan 
due to for instance domestic violence as well as the appreciable gender inequality that currently exists 
in Pakistan. This includes researching further the identification and management of female patients 
with psychotic illnesses in Pakistan such as schizophrenia and bipolar disorders in view of local 
sociocultural issues, endorsing recent suggestions (103).   
 
Risperidone was the most common prescribed atypical antipsychotic along with olanzapine, with little 
change in their overall utilization as a percentage of total units over the years in both the IMS data 
and the retrospective study (Tables 2 and 6), in line with WHO guidance (9). This is similar to other 
countries, although olanzapine may be more prescribed than risperidone (84, 85, 87). There is also 
increased prescribing of quetiapine and aripiprazole in Europe with, as mentioned, concerns with 
weight gain with olanzapine and risperidone (27, 57, 104, 105), although not seen yet in Pakistan 
(Tables 2 and 6). If anything, there was a significant decrease in the prescribing of aripiprazole in 
some years, although marginally increased prescribing in recent years, albeit from a limited base 
(Table 2).  
 
Overall, differences in prescribing habits within and between countries may be due to physician 
preferences, different patient responses to available treatments, availability of generic versus brand 
choices and costs (29, 35, 82). For typical antipsychotics, haloperidol was one of the commonest 
used medicines in both groups (Tables 2 and 6), which is similar to Canadian and Australian studies 
(84, 87), potentially enhanced by its inclusion in the WHO essential medicines list (9).   
 
Single antipsychotics were prescribed in 93.0% of patients (Table 5). However, there are concerns at 
the extent of polypharmacy seen with patients prescribed on average 4.56 medicines concurrently 
(Table 5); appreciably above the WHO target of 2 medicines (80). This is no doubt exacerbated by the 
extent of co-morbidities among the studied patients and the associated medicines (Table 8 and 
Appendix). The most common concomitant medicines prescribed with the antipsychotics were those 
affecting the central nervous system (Table 7). This is perhaps not surprising since patients with 
psychiatric disorders may also suffer from other mental and brain related conditions, increasing 
concomitant prescribing with medicines targeted for the central nervous system and resultant 
polypharmacy (Table 7). The second most common concomitant medicines prescribed were the anti-
muscarinic medicines. Whilst atypical antipsychotics are generally associated with less muscarinic 
side effects than typical ones, patients still experience these side-effects potentially explaining their 
joint prescribing. In addition, other comorbid conditions such as dizziness and dementia might require 
the use of anti-muscarinic medicines. As stated earlier, diabetes mellitus and hypertension were also 
common comorbidities in our patients, adding to the extent of polypharmacy (Table 8 and Appendix). 
Having said this, the rates of polypharmacy were high and this will be explored in future research with 
issues of compliance and adverse drug reactions being a concern with the increasing number of 
medicines prescribed (106-108).   
 
The low rate of INN prescribing, as well as the low rate of prescribing as suggested by the NEDL, are 
also concerns (Table 5). This will again be explored in more detail to ascertain the rationale behind 
this. However, we are aware that pharmacists typically suggest the brands that will give them the 
maximum benefit financially, especially with incentives from pharmaceutical companies to 
preferentially dispense their brand. Suggested strategies will subsequently be proposed based on 
successful approaches in other countries. These include measures to improve the quality of generics 
in Pakistan, ensuring a regular supply chain given concerns with counterfeits, as well as education 
among all key stakeholder groups (9, 98, 109, 110). The provision of mental health services in 
Pakistan will also be explored in more detail following critical guidance from the WHO and others, as 
well as concerns that female patients in particular may be missing out (9).   
 
Whilst we believe this is the first report exploring in depth the utilization of antipsychotics in Pakistan 
at a national and regional level in recent years, we are aware of a number of limitations with this 
study. Firstly, as with any retrospective study, some data were not available to make definitive 
conclusions especially with treatment outcomes, doses, tolerability, and side effects. Secondly, we 
could not follow up patient records to determine if the atypical antipsychotics being prescribed were 
first line or as a replacement for typical antipsychotics. Thirdly, we only undertook the study in two 
cities. Nevertheless, we believe our findings are robust with a good correlation between the 
retrospective study and IMS data, which will help formulate future strategies to better manage these 




The research showed an appreciable increase in the utilization of antipsychotics in Pakistan in recent 
years, which is encouraging. The atypical antipsychotics, olanzapine and risperidone, constituted 
more than two thirds of all antipsychotic prescriptions. In addition, almost all patients received one 
antipsychotic rather than multiple antipsychotics, in keeping with most standard therapeutic 
guidelines. However, further studies are required to examine the outcome of these prescriptions and 
their effects on metabolic and other physiologic profiles of patients. There is also a need to promote 
INN prescribing in Pakistan as well as enhance adherence to the NEDL. In addition, there is an urgent 
need to reduce the extent of unnecessary polypharmacy where this exists. These are issues for the 
future, along with a greater understanding of the types of patients with appreciable mental health 
issues either seeking, or not seeking, care from healthcare professionals in Pakistan. This will 
enhance our understanding of mental health issues in Pakistan to improve future treatment including 
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No. of patients 





     
         Diabetes 334  Metformin. 
 Sulfonylureas.  
 Meglitinides.  
 Insulin therapy. 
15.6 
   HTN(Hypertension) 313  Thiazide diuretics 
 Beta blockers. 
 Angiotensin-converting enzyme (ACE) 
inhibitors.  
 Angiotensin II receptor blockers 
(ARBs).  
 Calcium channel blockers. 
 Renin inhibitors. 
14.6 
     Diabetes+ HTN 147  Metformin. 
 Sulfonylureas.  
 Meglitinides.  
 Insulin therapy. 
 Thiazide diuretics 
 Beta blockers. 
 Angiotensin-converting enzyme (ACE) 
inhibitors.  
 Angiotensin II receptor blockers 
(ARBs).  
 Calcium channel blockers. 
 Renin inhibitors. 
6.7 
       CVD 
(Cardiovascular 
Disease 
190  ACE inhibitors 
 Aldosterone inhibitors  
 Angiotensin II receptor blockers 
(ARBs) 
 Beta-blockers 
 Calcium channel blockers 
 Cholesterol-lowering drugs 
8.9 
 Diabetes+ HTN+  
         CVD 
42  Metformin. 
 Sulfonylureas.  
 Meglitinides.  
 Insulin therapy. 
 Thiazide diuretics 
 Beta blockers. 
 Angiotensin II receptor blockers 
(ARBs).  
 Calcium channel blockers. 
 Renin inhibitors. 
 ACE inhibitors  
 Aldosterone inhibitors  
 Beta-blockers 
1.9 










 Diabetes 119  Metformin. 8.6 
 Sulfonylureas.  
 Meglitinides.  
 Insulin therapy. 
 HTN 122  Thiazide diuretics 
 Beta blockers. 
 Angiotensin-converting enzyme (ACE) 
inhibitors.  
 Angiotensin II receptor blockers 
(ARBs).  
 Calcium channel blockers. 
 Renin inhibitors. 
8.8 
 Diabetes+ HTN 103  Metformin. 
 Sulfonylureas.  
 Meglitinides.  
 Insulin therapy. 
 Thiazide diuretics 
 Beta blockers. 
 Angiotensin-converting enzyme (ACE) 
inhibitors.  
 Angiotensin II receptor blockers 
(ARBs).  
 Calcium channel blockers. 
 Renin inhibitors. 
7.4 
 CVD 87  ACE inhibitors  
 Aldosterone inhibitors  
 Angiotensin II receptor blockers 
(ARBs) 
 Beta-blockers 
 Calcium channel blockers 
6.2 
 Diabetes+ HTN+ 
CVD 
05  Metformin. 
 Sulfonylureas.  
 Meglitinides.  
 Insulin therapy. 
 Thiazide diuretics 
 Beta blockers. 
 Angiotensin II receptor blockers 
(ARBs).  
 Calcium channel blockers. 
 Renin inhibitors. 
 ACE inhibitors  
 Aldosterone inhibitors  
 Beta-blockers 
0.4 
 Migraine  27  Pain relievers. 
 Triptans.  
 Ergots 
 Anti-nausea 
 Opioid medications 
 Glucocorticoids 
1.9 
 Obesity  56  Beta-methyl-phenylethylamine  
 Lipase Inhibitor 
 Phentermine  
 Sibutramine 
4 
 Eating Disorders 44  Anticonvulsant topiramate 
 Selective serotonin reuptake inhibitors 
(SSRIs)  
3.2 
Depression          724   
 Diabetes 51  Metformin. 
 Sulfonylureas.  
 Meglitinides.  
 Insulin therapy. 
3.7 
 HTN 11  Thiazide diuretics 
 Beta blockers. 
 Angiotensin-converting enzyme (ACE) 
inhibitors.  
 Angiotensin II receptor blockers 
(ARBs).  
 Calcium channel blockers. 
 Renin inhibitors. 
0.8 
 Diabetes+ HTN 13  Metformin. 
 Sulfonylureas.  
 Meglitinides.  
 Insulin therapy. 
 Thiazide diuretics 
 Beta blockers. 
 Angiotensin-converting enzyme (ACE) 
inhibitors.  
 Angiotensin II receptor blockers 
(ARBs).  
 Calcium channel blockers. 
 Renin inhibitors. 
0.1 
 CVD 46  ACE inhibitors  
 Aldosterone inhibitors  
 Angiotensin II receptor blockers 
(ARBs) 
 Beta-blockers 
 Calcium channel blockers 
3,3 
 Diabetes+ HTN+ 
CVDs 
04  Metformin. 
 Sulfonylureas.  
 Meglitinides.  
 Insulin therapy. 
 Thiazide diuretics 
 Beta blockers. 
 Angiotensin II receptor blockers 
(ARBs).  
 Calcium channel blockers. 
 Renin inhibitors. 
 ACE inhibitors  
 Aldosterone inhibitors  
 Beta-blockers 
0.3 
 Hypothyroidism 32  Thioamides  
 Anion inhibitors 
 Iodides  
2.3 
 Obesity 21  Psychotropic appetite suppressant 
 Non- Psychotropic appetite suppressant 
 Impulse and craving suppressant  
 Lipase inhibitor 
1.5 
 Migraine 14  Pain relievers. 











 Diabetes 07  Metformin. 
 Sulfonylureas.  
 Meglitinides.  
 Insulin therapy. 
0.5 
 HTN 11  Thiazide diuretics 
 Beta blockers. 
 Angiotensin-converting enzyme (ACE) 
inhibitors.  
 Angiotensin II receptor blockers 
(ARBs).  
 Calcium channel blockers. 
 Renin inhibitors. 
0.8 
 Diabetes+ HTN 03  Metformin. 
 Sulfonylureas.  
 Meglitinides.  
 Insulin therapy. 
 Thiazide diuretics 
 Beta blockers. 
 Angiotensin-converting enzyme (ACE) 
inhibitors.  
 Angiotensin II receptor blockers 
(ARBs).  
 Calcium channel blockers. 
 Renin inhibitors. 
0.2 
 CVD 14  ACE inhibitors  
 Aldosterone inhibitors  
 Angiotensin II receptor blockers 
(ARBs) 
 Beta-blockers 
 Calcium channel blockers 
 Cholesterol-lowering drugs 
1 
 Diabetes+ HTN+ 
CVD 
02  Metformin. 
 Sulfonylureas.  
 Meglitinides.  
 Insulin therapy. 
 Thiazide diuretics 
 Beta blockers. 
 Angiotensin II receptor blockers 
(ARBs).  
 Calcium channel blockers. 
 Renin inhibitors. 
 ACE inhibitors  
 Aldosterone inhibitors  
 Beta-blockers 
 Cholesterol-lowering drugs 
0.1 
 IBS  02  0.1 









 Diabetes 06  Metformin. 7.2 
 Sulfonylureas.  
 Meglitinides.  
 Insulin therapy. 
 HTN 10  Thiazide diuretics 
 Beta blockers. 
 Angiotensin-converting enzyme (ACE) 
inhibitors.  
 Angiotensin II receptor blockers 
(ARBs).  
 Calcium channel blockers. 
 Renin inhibitors. 
12 
 Diabetes+HTN 04  Metformin. 
 Sulfonylureas.  
 Meglitinides.  
 Insulin therapy. 
 Thiazide diuretics 
 Beta blockers. 
 Angiotensin-converting enzyme (ACE) 
inhibitors.  
 Angiotensin II receptor blockers 
(ARBs).  
 Calcium channel blockers. 
 Renin inhibitors. 
4.8 
 CVD 08  ACE inhibitors  
 Aldosterone inhibitors  
 Angiotensin II receptor blockers 
(ARBs) 
 Beta-blockers 
 Calcium channel blockers 
 Cholesterol-lowering drugs 
9.6 
 Diabetes+ HTN+ 
CVD 
08  Metformin. 
 Sulfonylureas.  
 Meglitinides.  
 Insulin therapy. 
 Thiazide diuretics 
 Beta blockers. 
 Angiotensin II receptor blockers 
(ARBs).  
 Calcium channel blockers. 
 Renin inhibitors. 
 ACE inhibitors  
 Aldosterone inhibitors  
 Beta-blockers 
9.6 
 Gastric Problems 12  Proton pump Inhibitors 14.4 
 Migraine 04  Pain relievers. 
 Triptans.  
 Anti-nausea 








 Obesity 07  Psychotropic appetite suppressant 
 Non- Psychotropic appetite suppressant 
 Lipase inhibitor 
0.7 
 Smoking 32  3.3 
 Eating Disorders 15  Anticonvulsant topiramate 1.5 
  Selective serotonin reuptake inhibitors 
(SSRIs) 
